Prostate Cancer Survival: Enzalutamide Edges Out Abiraterone

M. Alexander Otto, PA, MMS

May 20, 2022

The study was published on researchsquare.com as a preprint and has not yet been peer reviewed.

Men with metastatic castration-resistant prostate cancer (mCRPC) who began treatment on enzalutamide instead of abiraterone remained on treatment longer and lived a few more months.

To continue reading this article ...

Continue reading your article with a Medscape account

Join the Top Medical Resource for Physicians Today. Free Membership!

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.